# Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma

> **NCT07514767** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Prof. Lars Olaf Cardell** · enrollment: 60 (estimated)

## Conditions studied

- Oral Squamous Cell Carcinoma (OSCC)

## Interventions

- **DRUG:** Nivolumab (240 mg)

## Key facts

- **NCT ID:** NCT07514767
- **Lead sponsor:** Prof. Lars Olaf Cardell
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-09
- **Final completion:** 2033-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07514767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07514767, "Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07514767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*